UPDATE: Intellia Therapeutics (NTLA) PT Lowered to $83 at Morgan Stanley (correction)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
- Array Technologies and Shoals Technologies agree to stock-for-stock merger
- AMD gets bullish pre-earnings call from Lynx as server CPU demand accelerates
- Intel shares fall as competitor reports record results
- Marathon Petroleum to sell two refineries to CVR Energy for $4.2B
- AMD forecast eases AI spending fears as data-center sales surge
- After-Hours Movers: AMD, SMCI, SWKS, NRIX, TOST, BKNG
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
Intellia Therapeutics (NTLA) PT Lowered to $53 at Wedbush
November 3, 2022 11:36 AM EDTWedbush analyst David Nierengarten lowered the price target on Intellia Therapeutics (NASDAQ: NTLA) to $53.00 (from $58.00) while maintaining a Neutral rating.... More
Intellia Therapeutics (NTLA) Misses Q3 EPS by 20c
November 3, 2022 7:36 AM EDTIntellia Therapeutics (NASDAQ: NTLA) reported Q3 EPS of ($1.49), $0.20 worse than the analyst estimate of ($1.29). Revenue for the quarter came in at $13.27 million versus the consensus estimate of $11.43 million.
For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.
... More


